Research and Development

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA

August 1, 2024 Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma

Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …

News

Press release

Eisai presents latest findings for lecanemab at Alzheimer’s Association International Conference (AAIC)

July 31, 2024 Research and Development Alzheimers, Conference results, Eisai, Neurology

Clarity AD open-label extension (OLE) data show: three years of continuous lecanemab treatment reduced clinical decline by -0.95 vs expected …

News

Press release

Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University

July 31, 2024 Clinical Research, Medical Communications, Research and Development Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research

Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s …

News

FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products

July 31, 2024 Media Relations, Medical Communications, Pharmacovigilance, US Healthcare & Trade Press FDA, Gastrointestinal tract, compunded injectable, dosage, hospitalisation, pharmaceutical, warning

This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing errors associated with compounded injectable …

News

AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax

July 30, 2024 Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis

AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …

News

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation

July 29, 2024 Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …

News

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma

July 29, 2024 Research and Development ADC, CHMP, Merck, Oncology, Urology, keytruda, metastatic urothelial carcinoma, unresectable urothelial carcinoma

Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 therapy, in combination with Padcev …

News

Calliditas Therapeutics announces positive phase 2b data in Primary Biliary Cholangitis trial

July 26, 2024 Research and Development Calliditas, Hepatology, clinical trials, elevated liver stiffness, primary biliary cholangitis

Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …

News

AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA

July 26, 2024 Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein

Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …

News

ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy

July 23, 2024 Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy

GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …

News

Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM

July 22, 2024 Research and Development Altuviiio, Haematology, Sanofi, haemophilia

Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …

News

Brainomix and Boehringer Ingelheim enter strategic partnership

July 19, 2024 Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership

Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …

News

Camurus shares phase 3 results from ACROINNOVA 2 study

July 16, 2024 Research and Development Camurus, Pharmacy, acromegaly, clinical trial, injection

Camurus has announced positive results from its 52-week phase 3 open-label ACROINNOVA 2 study, which assessed the safety and efficacy …

News

AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding

July 15, 2024 Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding

Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …

News

ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models

July 15, 2024 Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug

Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …

News